Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE)
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pre-treatment inflammatory markers, specifically the systemic inflammatory response index (SIRI) and lymphocyte to monocyte ratio (LMR), can predict treatment outcomes for hepatocellular carcinoma (HCC) patients undergoing degradable starch microspheres transarterial chemoembolization (DSM-TACE). Elevated LMR and reduced SIRI are associated with improved overall survival in specific patient subgroups.
Area Of Science
- Hepatobiliary Oncology
- Interventional Radiology
- Cancer Biomarkers
Background
- Hepatocellular carcinoma (HCC) is a primary liver cancer with variable treatment responses.
- Transarterial chemoembolization with degradable starch microspheres (DSM-TACE) is a standard treatment for unresectable HCC.
- Identifying predictive biomarkers for DSM-TACE efficacy is crucial for personalized treatment strategies.
Purpose Of The Study
- To investigate the prognostic significance of pre-therapeutic inflammatory markers in HCC patients treated with DSM-TACE.
- To determine if systemic inflammatory response index (SIRI) and lymphocyte to monocyte ratio (LMR) predict overall survival (OS) after DSM-TACE.
- To explore the utility of these markers in stratifying patients for optimized treatment selection.
Main Methods
- Retrospective analysis of 155 HCC patients undergoing first-time DSM-TACE.
- Evaluation of pre-treatment inflammatory indices, including SIRI and LMR, dichotomized by median values.
- Statistical analysis using Cox proportional hazard models (univariate and multivariate) and Kaplan-Meier survival analysis.
Main Results
- Median overall survival (OS) for the cohort was 15.9 months, varying significantly by BCLC stage.
- In multivariate analysis, lower SIRI (HR: 0.41) and higher LMR (HR: 0.44) were independently associated with improved OS, alongside BCLC stage, ALBI grade, tumor burden, and lesion size.
- Subgroup analysis revealed significantly prolonged OS in BCLC B and Child-Pugh A patients with elevated LMR and reduced SIRI.
Conclusions
- Pre-treatment SIRI and LMR are valuable prognostic indicators for HCC patients undergoing DSM-TACE.
- These inflammatory markers can help identify BCLC B and Child-Pugh A patients who may benefit most from DSM-TACE.
- Further research is warranted to validate these findings and refine their clinical application.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.